Browse News
Filter News
Found 809,084 articles
-
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
-
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
-
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
4/24/2024
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 in patients living with Treatment Resistant Depression.
-
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
4/24/2024
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
-
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
4/24/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the second and final tranche of its private placement financing of Units for $3.8 million representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024.
-
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
4/24/2024
Chimerix announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.
-
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
4/24/2024
PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.
-
Thermo Fisher Scientific Reports First Quarter 2024 Results
4/24/2024
Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the first quarter ended March 30, 2024.
-
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
4/24/2024
Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors.
-
BioInvent International AB: Interim Report January-March 2024
4/24/2024
During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.
-
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
4/24/2024
Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
-
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad
4/24/2024
Spago Nanomedical AB announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer.
-
Esaote Group: Shareholders' Meeting approves financial statements as of 31 December 2023
4/24/2024
The Shareholders' Meeting of Esaote S.p.A., met in Genoa, approved the company's financial statements as of 31.12.2023.
-
Angle PLC Announces New Commercial Agreement with AstraZeneca
4/24/2024
ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
-
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
4/24/2024
AAVantgarde Bio announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting, to be held May 5-9 in Seattle.
-
Atom Bioscience Enrolling Patients in US as Part of a Global Phase 2b/3 Clinical Trial of a New Investigational Treatment for Chronic Gout
4/24/2024
Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, has begun enrolling patients in the US for in a Phase 2b/3 clinical trial of ABP-671, a novel investigational orally administered URAT1 inhibitor, for the treatment of chronic gout.
-
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
4/24/2024
Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.